Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy

Takako Shimada, Toshiaki Saito, Mototsugu Shimokawa, Kumi Shimamoto, Shuhei Matsushita, Shinichiro Yamaguchi, Kazuya Ariyoshi, Masao Okadome

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The prognosis of ovarian cancer has improved because of platinum- and taxanecontainingchemotherapy. We investigated the 5-year disease-specific overall survival and prognosticfactors of patients with advanced ovarian cancer to elucidate the change in clinical courseof ovarian cancer with the advance of chemotherapy for patients who developed relapse in theera before the addition of molecular targeting therapy.Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGOStage III and IV) treated in the past 11 years (1999-2010). We classified the patients into twogroups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) andthose who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecificoverall survival and median survival rates between these two groups. We also investigatedthe prognostic factors of 104 patients who developed relapse.Results: The 5-year disease-specific overall survival rate was significantly higher in Group B thanA (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride,non-clear cell adenocarcinoma and intestinal resection were independent prognosticfactors.Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondorthird-line chemotherapy affected the improvement in overall survival of patients with advancedepithelial ovarian cancer.

Original languageEnglish
Article numberhyx026
Pages (from-to)494-498
Number of pages5
JournalJapanese journal of clinical oncology
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Ovarian Neoplasms
Drug Therapy
Survival
Therapeutics
Survival Rate
Recurrence
Platinum
Doxorubicin
Adenocarcinoma
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Shimada, T., Saito, T., Shimokawa, M., Shimamoto, K., Matsushita, S., Yamaguchi, S., ... Okadome, M. (2017). Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. Japanese journal of clinical oncology, 47(6), 494-498. [hyx026]. https://doi.org/10.1093/jjco/hyx026

Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. / Shimada, Takako; Saito, Toshiaki; Shimokawa, Mototsugu; Shimamoto, Kumi; Matsushita, Shuhei; Yamaguchi, Shinichiro; Ariyoshi, Kazuya; Okadome, Masao.

In: Japanese journal of clinical oncology, Vol. 47, No. 6, hyx026, 01.06.2017, p. 494-498.

Research output: Contribution to journalArticle

Shimada, T, Saito, T, Shimokawa, M, Shimamoto, K, Matsushita, S, Yamaguchi, S, Ariyoshi, K & Okadome, M 2017, 'Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy', Japanese journal of clinical oncology, vol. 47, no. 6, hyx026, pp. 494-498. https://doi.org/10.1093/jjco/hyx026
Shimada, Takako ; Saito, Toshiaki ; Shimokawa, Mototsugu ; Shimamoto, Kumi ; Matsushita, Shuhei ; Yamaguchi, Shinichiro ; Ariyoshi, Kazuya ; Okadome, Masao. / Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. In: Japanese journal of clinical oncology. 2017 ; Vol. 47, No. 6. pp. 494-498.
@article{9be799a23314462e9a3ba7c9e039241a,
title = "Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy",
abstract = "Objective: The prognosis of ovarian cancer has improved because of platinum- and taxanecontainingchemotherapy. We investigated the 5-year disease-specific overall survival and prognosticfactors of patients with advanced ovarian cancer to elucidate the change in clinical courseof ovarian cancer with the advance of chemotherapy for patients who developed relapse in theera before the addition of molecular targeting therapy.Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGOStage III and IV) treated in the past 11 years (1999-2010). We classified the patients into twogroups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) andthose who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecificoverall survival and median survival rates between these two groups. We also investigatedthe prognostic factors of 104 patients who developed relapse.Results: The 5-year disease-specific overall survival rate was significantly higher in Group B thanA (67.0{\%} vs. 38.6{\%}; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride,non-clear cell adenocarcinoma and intestinal resection were independent prognosticfactors.Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondorthird-line chemotherapy affected the improvement in overall survival of patients with advancedepithelial ovarian cancer.",
author = "Takako Shimada and Toshiaki Saito and Mototsugu Shimokawa and Kumi Shimamoto and Shuhei Matsushita and Shinichiro Yamaguchi and Kazuya Ariyoshi and Masao Okadome",
year = "2017",
month = "6",
day = "1",
doi = "10.1093/jjco/hyx026",
language = "English",
volume = "47",
pages = "494--498",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy

AU - Shimada, Takako

AU - Saito, Toshiaki

AU - Shimokawa, Mototsugu

AU - Shimamoto, Kumi

AU - Matsushita, Shuhei

AU - Yamaguchi, Shinichiro

AU - Ariyoshi, Kazuya

AU - Okadome, Masao

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objective: The prognosis of ovarian cancer has improved because of platinum- and taxanecontainingchemotherapy. We investigated the 5-year disease-specific overall survival and prognosticfactors of patients with advanced ovarian cancer to elucidate the change in clinical courseof ovarian cancer with the advance of chemotherapy for patients who developed relapse in theera before the addition of molecular targeting therapy.Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGOStage III and IV) treated in the past 11 years (1999-2010). We classified the patients into twogroups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) andthose who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecificoverall survival and median survival rates between these two groups. We also investigatedthe prognostic factors of 104 patients who developed relapse.Results: The 5-year disease-specific overall survival rate was significantly higher in Group B thanA (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride,non-clear cell adenocarcinoma and intestinal resection were independent prognosticfactors.Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondorthird-line chemotherapy affected the improvement in overall survival of patients with advancedepithelial ovarian cancer.

AB - Objective: The prognosis of ovarian cancer has improved because of platinum- and taxanecontainingchemotherapy. We investigated the 5-year disease-specific overall survival and prognosticfactors of patients with advanced ovarian cancer to elucidate the change in clinical courseof ovarian cancer with the advance of chemotherapy for patients who developed relapse in theera before the addition of molecular targeting therapy.Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGOStage III and IV) treated in the past 11 years (1999-2010). We classified the patients into twogroups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) andthose who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year diseasespecificoverall survival and median survival rates between these two groups. We also investigatedthe prognostic factors of 104 patients who developed relapse.Results: The 5-year disease-specific overall survival rate was significantly higher in Group B thanA (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride,non-clear cell adenocarcinoma and intestinal resection were independent prognosticfactors.Conclusions: The induction of new chemotherapeutic drugs and the increased variation of secondorthird-line chemotherapy affected the improvement in overall survival of patients with advancedepithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85021326639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021326639&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx026

DO - 10.1093/jjco/hyx026

M3 - Article

C2 - 28334884

AN - SCOPUS:85021326639

VL - 47

SP - 494

EP - 498

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

M1 - hyx026

ER -